NCT00099086 is a Phase 1 clinical trial of Bicalutamide in Prostate Cancer, sponsored by Medical University of South Carolina.

Who is sponsoring NCT00099086?

NCT00099086 is sponsored by Medical University of South Carolina.

What drugs are being tested in NCT00099086?

Interventions in NCT00099086: Bicalutamide, docetaxel, GnRh analog, radiotherapy.

What condition does NCT00099086 study?

NCT00099086 studies Prostate Cancer.

Is NCT00099086 still recruiting?

NCT00099086 is currently completed. Last updated 31 January 2024.

Last reviewed 2024-01-31 · How we verify

NCT00099086

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Completed Phase 1 Last updated 31 January 2024

What this trial tests

Phase 1 trial testing Bicalutamide in Prostate Cancer in 20 participants. Completed in 13 December 2023.

Timeline

16 January 2007

Primary endpoint
20 January 2011

13 December 2023

Quick facts

Lead sponsor	Medical University of South Carolina
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	16 January 2007
Primary completion	20 January 2011
Estimated completion	13 December 2023

Drugs / interventions tested

Bicalutamide (bicalutamide) — full drug profile →
docetaxel (Docetaxel) — full drug profile →
GnRh analog (gnrh-analog) — full drug profile →
radiotherapy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Medical University of South Carolina

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial is studying the side effects and best dose of docetaxel when given with radiation therapy and hormone therapy in patients with locally advanced prostate cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions.
Greenberger BA, Chen VE, Den RB. · · 2019 · cited 3× · PMID 31850194 · DOI 10.3389/fonc.2019.01273

Verify or expand the search:

Other trials of Bicalutamide

Trials testing the same drug.

NCT06528210 — Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized · Phase 2 · withdrawn
NCT06501911 — A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma · Phase 1 · withdrawn
NCT06650579 — REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial · Phase 3 · recruiting
NCT05327647 — A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT05050084 — Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients · Phase 3 · active not recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Medical University of South Carolina trials

Trials by the same sponsor.

NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00099086 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 31 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00099086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing